Different Effects of Transdermal and Oral Hormone Replacement Therapy on the Renin-Angiotensin System, Plasma Bradykinin Level, and Blood Pressure of Normotensive Postmenopausal Women

American Journal of Hypertension

Volumn 19, Issue 7, 2006, Pages 744-749

  Ichikawa, Junko ^a   Sumino, Hiroyuki ^b   Ichikawa, Shuichi ^b   Ozaki, Makoto ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Cardiovasc Hosp of Central Japan   (Japan)

Author keywords

Blood pressure; bradykinin; estrogen; postmenopausal women; renin angiotensin system

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; BRADYKININ; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE; ESTRADIOL; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; PLASMA RENIN ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSDERMAL PATCH; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ANGIOTENSIN I; ANGIOTENSIN II; BLOOD PRESSURE; BRADYKININ; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RENIN-ANGIOTENSIN SYSTEM;

EID: 33745249117     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.10.006     Document Type: Article

References (33)

1. Chetkowski R.J., Meldrum D.R., Steingold K.A., Randle D., Lu J.K., Eggena P., Hershman J.M., Alkjaersig N.K., Fletcher A.P., and Judd H.L. Biologic effects of transdermal estradiol. N Engl J Med 314 (1986) 1615-1620
2. Schunkert H., Danser A.H.J., Hense H.W., Derkx F.H.M., Kurzinger S., and Riegger G.A.J. Effects of estrogen replacement therapy on the rennin-angiotensin system in postmenopausal women. Circulation 95 (1997) 39-45
3. Hassager C., Riis B.J., Strom V., Guyene T.T., and Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma rennin substrate and blood pressure. Circulation 76 (1987) 753-758
4. Umeda M., Ichikawa S., Kanda T., Sumino H., and Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens 14 (2001) 206-211
5. Sumino H., Ichikawa S., Ohyama Y., Nakamura T., Kanda T., Sakamoto H., Sakamaki T., Mizunuma H., and Kurabayashi M. Effects of hormone replacement therapy on serum angiotensin-converting enzyme activity and plasma bradykinin in postmenopausal women according to angiotensin-converting enzyme-genotype. Hypertens Res 26 (2003) 53-58
6. Seely E.W., Walsh B.W., Gerhard M.D., and Williams G.H. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 33 (1999) 1190-1194
7. Faguer de Moustier B., Conard J., Guyene T.T., Sitt Y., Denys I., Arnoux-Rouveyre M., and Pelissier C. Comparative metabolic study of percutaneous versus oral micronized 17β-oestradiol in replacement therapy. Maturitas 11 (1989) 275-286
8. Proudler A.J., Ahmed A.I.H., Crook D., Fogelman I., Rymer J.M., and Stevenson J.C. Hormone replacement therapy and serum angiotensin-enzyme activity in postmenopausal women. Lancet 346 (1995) 89-90
9. Sumino H., Ichikawa S., Kanda T., Sakamaki T., Nakamura T., Sato K., Kobayashi I., and Nagai R. Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin. Am J Hypertens 12 (1999) 1044-1147
10. Nogawa N., Sumino H., Ichikawa S., Kumakura H., Takayama Y., Nakamura T., Kanda T., Mizunuma H., and Kurabayashi M. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause 8 (2001) 210-215
11. Proudler A.J., Cooper A., Whitehead M., and Stevenson J.C. Effects of oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clin Endocr 58 (2003) 30-35
12. Nachtigall L.E. Emerging delivery systems for estrogen replacement. aspects of transdermal and oral delivery. Am J Obstet Gynecol 173 (1995) 993-997
13. Koh K.K., Mincemoyer R., Bui M.N., Csako G., Pucino F., Guetta V., Waclawiw M., and Cannon III R.O. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336 (1997) 683-690
14. Vehkavaara S., Sliveria A., Hakala-Ala-Pietila T., Virkamaki A., Hovatta O., Hamsten A., Taskinen M.R., and Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on makers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85 (2001) 619-625
15. Power M.S., Schenkel L., Darley P.E., Good W.R., Balestra J.C., and Place V.A. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol. Comparsion with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 152 (1985) 1099-1106
16. Chetkowski R.J., Meldrum D.R., Steingold K.A., Randle D., Lu J.K., Eggena P., Hershman J.M., Alkjaersig N.K., Fletcher A.P., and Judd H.L. Biologic effects of transdermal estradiol. N Engl J Med 314 (1986) 1615-1620
17. Yamamoto T., Hiromoto J., Kikuchi Y., Oka M., and Takatori O. Correlations among blood levels of renin-angiotensin-aldosterone, bradykinin, and catecholamines in healthy subjects. Clin Chim Acta 181 (1989) 197-200
18. Sumino H., Ichikawa S., Sakamato H., Sawada Y., Kumakura H., Takayama Y., Sakamaki T., and Kurabayashi M. Effects of conjugated equine estrogen and medroxyprogesterone acetate on lipoprotein(a) and other lipoproteins in Japanese postmenopausal women with and without dyslipidemia. Horm Res 62 (2004) 1-9
19. Kasahara Y., and Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 27 (1981) 1922-1925
20. Akkad A.A., Halligan A.W.F., Abrams K., and Al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol 89 (1997) 97-103
21. Vongpatanasin W., Tuncel M., Mansour Y., Arbique D., and Victor R.G. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 103 (2001) 2903-2908
22. Mikkola T., Viinikka L., and Ylikorkala O. Estrogen and postomenopausal estrogen/progestion therapy. effect on endothelium-dependent prostacyclin, nitiric oxide and endothelin-1 production. Eur J Obstet Gynecol Reprod Biol 79 (1998) 75-82
23. Dean S.A., Tan J., O'Brien E.R., and Leenen F.H.H. 17β-Estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 288 (2005) R759-R766
24. Owonikoko T.K., Fabucci M.E., Brown P.R., Nisar N., Hilton J., Mathews W.B., Ravert H.T., Rauseo P., Sandberg K., Dannals R.F., and Szabo Z. In vivo investigation of estrogen regulation of adrenal and renal angiotensin receptor expression by PET. J Nucl Med 45 (2004) 94-100
25. Sumino H., Ichikawa S., Miya Y., Sakamaki T., and Kurabayashi M. Angiotensin II plays an important role in maintaining blood pressure in postmenopausal women receiving hormone replacement therapy. Am J Hypertens 18 (2005) 1340-1346
26. Campbell D.J. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 28 (2001) 1060-1065
27. Tschope C., Schultheiss H.P., and Walther T. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems. role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 39 (2002) 478-487
28. Hully S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E., and Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estorogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 280 (1998) 605-613
29. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288 (2002) 321-333
30. Unger T. The role of the renin-angiotenisn system in the development of cardiovascular disease. Am J Cardiol 89 (2002) 3A-9A
31. Miura S., Saku K., and Karnik S.S. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 26 (2003) 937-943
32. Cook N.R., Cohen J., Hebert P.R., Taylor J.O., and Hennekens C.H. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 155 (1995) 701-709
33. Sealey J.E. Plasma renin activity and plasma prorenin assays. Clin Chem 37 (1991) 1811-1819